- Home
- GRF vs ELUT Comparison
GRF vs ELUT Comparison
Compare GRF & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRF | ELUT |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.9M | 45.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GRF | ELUT |
|---|---|---|
| Price | $10.26 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 2.0K | ★ 153.5K |
| Earning Date | 01-01-0001 | 03-11-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | ★ 1.16 | 0.87 |
| Revenue | N/A | ★ $12,293,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.83 |
| P/E Ratio | $8.62 | ★ $1.23 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.86 | $0.50 |
| 52 Week High | $11.85 | $2.99 |
Technical Indicators
Market Signals| Indicator | GRF | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 44.23 | 48.02 |
| Support Level | $9.96 | $0.86 |
| Resistance Level | $11.00 | $1.16 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 48.88 | 21.54 |
Price Performance
Historical ComparisonAbout GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.